Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

PARP inhibitors

  • Open Access
    Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
    MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA
    Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
  • You have access
    Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study
    ANGIOLO GADDUCCI, STEFANIA COSIO, FABIO LANDONI, ANDREA ALBERTO LISSONI, PAOLO ZOLA, MARIA ELENA LAUDANI, ANTONIO ARDIZZOIA, ANGELA GAMBINO and ENRICO SARTORI
    Anticancer Research April 2022, 42 (4) 2017-2022; DOI: https://doi.org/10.21873/anticanres.15681
  • You have access
    PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review
    CAIO BEZERRA MACHADO, EMERSON LUCENA DA SILVA, MANOEL ODORICO DE MORAES FILHO, MARIA ELISABETE AMARAL DE MORAES and CAROLINE AQUINO MOREIRA-NUNES
    Anticancer Research June 2020, 40 (6) 3055-3063; DOI: https://doi.org/10.21873/anticanres.14286
  • You have access
    PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research
    ANGIOLO GADDUCCI and MARIA ELENA GUERRIERI
    Anticancer Research May 2016, 36 (5) 2055-2064;
  • You have access
    Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now?
    JOHN SYRIOS, SUSANA BANERJEE and STANLEY B. KAYE
    Anticancer Research May 2014, 34 (5) 2069-2077;
  • You have access
    Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines
    EWA JASEK, MARIUSZ GAJDA, GRZEGORZ J. LIS, MAŁGORZATA JASIŃSKA and JAN A. LITWIN
    Anticancer Research April 2014, 34 (4) 1849-1856;
  • You have access
    ‘BRCAness’ and Its Implications for Platinum Action in Gynecologic Cancer
    FRANCO MUGGIA and TAMAR SAFRA
    Anticancer Research February 2014, 34 (2) 551-556;
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire